The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The addition of the bispecific T-cell engager blinatumomab to consolidation chemotherapy in adults patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) who had
For the first time in history, the Society of Hematologic Oncology (SOHO) is holding a joint session with the Brazilian Association of Hematology,
